CA2834243C - Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody - Google Patents
Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody Download PDFInfo
- Publication number
- CA2834243C CA2834243C CA2834243A CA2834243A CA2834243C CA 2834243 C CA2834243 C CA 2834243C CA 2834243 A CA2834243 A CA 2834243A CA 2834243 A CA2834243 A CA 2834243A CA 2834243 C CA2834243 C CA 2834243C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- ser
- cell
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-101752 | 2011-04-28 | ||
| JP2011101752 | 2011-04-28 | ||
| PCT/JP2012/061795 WO2012148003A1 (en) | 2011-04-28 | 2012-04-27 | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2834243A1 CA2834243A1 (en) | 2012-11-01 |
| CA2834243C true CA2834243C (en) | 2019-08-27 |
Family
ID=46147004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2834243A Active CA2834243C (en) | 2011-04-28 | 2012-04-27 | Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9803026B2 (enExample) |
| EP (2) | EP3232202B1 (enExample) |
| JP (2) | JP6001557B2 (enExample) |
| KR (1) | KR101873614B1 (enExample) |
| CN (1) | CN103703372B (enExample) |
| AU (2) | AU2012248158C1 (enExample) |
| CA (1) | CA2834243C (enExample) |
| ES (2) | ES2638088T3 (enExample) |
| HU (2) | HUE054211T2 (enExample) |
| IL (1) | IL229127A (enExample) |
| MX (1) | MX352599B (enExample) |
| PL (2) | PL3232202T3 (enExample) |
| PT (2) | PT2702412T (enExample) |
| RU (2) | RU2715642C2 (enExample) |
| SG (3) | SG10202108240VA (enExample) |
| WO (1) | WO2012148003A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2694018T3 (es) | 2007-07-02 | 2018-12-17 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el tratamiento y el diagnóstico del cáncer |
| WO2012148003A1 (en) * | 2011-04-28 | 2012-11-01 | Sbi Biotech Co., Ltd. | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
| WO2013012747A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| CN104854132A (zh) | 2012-07-13 | 2015-08-19 | 昂考梅德药品有限公司 | Rspo3结合剂及其用途 |
| ES2817897T3 (es) * | 2012-07-23 | 2021-04-08 | La Jolla Inst Allergy & Immunology | PTPRS y proteoglicanos en enfermedad autoinmune |
| US11160873B2 (en) * | 2014-02-04 | 2021-11-02 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| EP3102940B1 (en) * | 2014-02-04 | 2019-06-26 | Monash University | Anti-metalloprotease antibody for diagnosis and treatment of cancers |
| WO2016044295A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| BR112017011170A2 (pt) * | 2014-12-18 | 2018-02-27 | Hoffmann La Roche | método para determinar a citotoxicidade dependente do complemento de uma composição |
| MX2019011252A (es) * | 2017-03-23 | 2020-01-23 | Univ Pennsylvania | Anticuerpos anti-c5a y usos de los mismos. |
| EP3599843A4 (en) * | 2017-03-24 | 2021-01-13 | The Regents of the University of California | PROTEOGLYCAN IRREGULARITIES IN ABNORMAL FIBROBLASTS AND THERAPIES BASED ON THEM |
| US11242398B2 (en) | 2017-08-01 | 2022-02-08 | Remd Biotherapeutics, Inc. | Anti-OX40 antibodies and methods of activating OX40 |
| WO2020023679A1 (en) * | 2018-07-25 | 2020-01-30 | Accurus Biosciences, Inc. | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| EP4037712A4 (en) | 2019-10-04 | 2023-11-01 | Albert Einstein College of Medicine | KIR3DL3 IS AN IMMUNE SYSTEM INHIBITANT RECEPTOR AND USES THEREOF |
| CA3225321A1 (en) | 2021-07-30 | 2023-02-02 | Nunzio Bottini | Ptprs in autoimmunity |
| CN114426582B (zh) * | 2022-01-07 | 2022-11-25 | 陕西脉元生物科技有限公司 | 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用 |
| CN116041526B (zh) * | 2022-11-14 | 2023-09-29 | 华中农业大学 | 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用 |
| WO2024124164A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells |
| EP4676980A2 (en) * | 2023-03-03 | 2026-01-14 | Case Western Reserve University | Cell adhesion molecule targeted immunotherapies |
| CN117050170A (zh) * | 2023-08-16 | 2023-11-14 | 武汉生物制品研究所有限责任公司 | 靶向识别白喉毒素的中和单克隆抗体8h6及其应用 |
| CN118994384B (zh) * | 2024-08-09 | 2025-09-26 | 陕西脉元生物科技有限公司 | 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法 |
| CN119874900B (zh) * | 2025-03-06 | 2025-10-17 | 吉林大学 | 一种单克隆抗体及其在制备治疗肿瘤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0721352A4 (en) | 1993-10-01 | 1998-07-01 | Univ New York | NEW PHOSPHOTYROSINE PHOSPHATASE - -g (s) WITH RECEPTOR FUNCTION |
| WO2004013325A1 (ja) | 2002-08-01 | 2004-02-12 | Ginkgo Biomedical Research Institute Co., Ltd. | マウスインターフェロン産生細胞の検出方法 |
| JPWO2004081047A1 (ja) * | 2003-03-14 | 2006-06-29 | 大正製薬株式会社 | モノクローナル抗体及びこれを産生するハイブリドーマ |
| CA2561073C (en) | 2004-03-27 | 2014-01-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| CA2622772A1 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| WO2009003274A1 (en) * | 2007-06-29 | 2009-01-08 | The Hospital For Sick Children | Susceptibility gene for inflammatory bowel disease |
| ES2796111T3 (es) * | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
| US20120231014A1 (en) * | 2009-08-18 | 2012-09-13 | Case Western Reserve University | Neural Regeneration |
| WO2011097327A2 (en) * | 2010-02-02 | 2011-08-11 | La Jolla Institute For Allergy & Immunology | Compositions and methods of modulating receptor protein tyrosine phosphatases |
| WO2012148003A1 (en) * | 2011-04-28 | 2012-11-01 | Sbi Biotech Co., Ltd. | ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY |
-
2012
- 2012-04-27 WO PCT/JP2012/061795 patent/WO2012148003A1/en not_active Ceased
- 2012-04-27 SG SG10202108240VA patent/SG10202108240VA/en unknown
- 2012-04-27 SG SG2013079066A patent/SG194614A1/en unknown
- 2012-04-27 ES ES12722557.1T patent/ES2638088T3/es active Active
- 2012-04-27 CA CA2834243A patent/CA2834243C/en active Active
- 2012-04-27 EP EP17174348.7A patent/EP3232202B1/en active Active
- 2012-04-27 HU HUE17174348A patent/HUE054211T2/hu unknown
- 2012-04-27 CN CN201280020580.XA patent/CN103703372B/zh active Active
- 2012-04-27 MX MX2013012393A patent/MX352599B/es active IP Right Grant
- 2012-04-27 AU AU2012248158A patent/AU2012248158C1/en active Active
- 2012-04-27 RU RU2017118262A patent/RU2715642C2/ru active
- 2012-04-27 SG SG10201503257WA patent/SG10201503257WA/en unknown
- 2012-04-27 JP JP2013549652A patent/JP6001557B2/ja active Active
- 2012-04-27 PT PT127225571T patent/PT2702412T/pt unknown
- 2012-04-27 EP EP12722557.1A patent/EP2702412B1/en active Active
- 2012-04-27 HU HUE12722557A patent/HUE034752T2/en unknown
- 2012-04-27 PT PT171743487T patent/PT3232202T/pt unknown
- 2012-04-27 US US14/113,904 patent/US9803026B2/en active Active
- 2012-04-27 PL PL17174348T patent/PL3232202T3/pl unknown
- 2012-04-27 PL PL12722557T patent/PL2702412T3/pl unknown
- 2012-04-27 ES ES17174348T patent/ES2788183T3/es active Active
- 2012-04-27 RU RU2013152816/10A patent/RU2013152816A/ru not_active Application Discontinuation
- 2012-04-27 KR KR1020137028325A patent/KR101873614B1/ko active Active
-
2013
- 2013-10-28 IL IL229127A patent/IL229127A/en active IP Right Grant
-
2016
- 2016-09-01 JP JP2016170634A patent/JP6412072B2/ja active Active
- 2016-11-23 AU AU2016262677A patent/AU2016262677B2/en active Active
-
2017
- 2017-10-06 US US15/726,669 patent/US10730955B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2715642C2 (ru) | АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА | |
| US12312410B2 (en) | Anti-CD39 antibodies | |
| CN111788225B (zh) | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 | |
| CN106715471B (zh) | 抗cd127的抗体 | |
| CN113906052B (zh) | 一种抗ceacam5的单克隆抗体及其制备方法和用途 | |
| TWI654201B (zh) | Ｐｄ－１抗體、其抗原結合片段及其醫藥用途 | |
| KR101931591B1 (ko) | 항－ｉｌ－２３ 항체 | |
| CN115151570B (zh) | 抗人cd19抗体 | |
| CN101952426B (zh) | 抗bst2抗体 | |
| KR20190059958A (ko) | 항-lag-3 항체 및 조성물 | |
| KR20170064550A (ko) | 인간화 항-ox40 항체 및 이의 용도 | |
| CN106795223B (zh) | 针对Fcγ受体IIB及Fcε受体的抗体 | |
| TW202210520A (zh) | 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用 | |
| JP2023513200A (ja) | 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用 | |
| CN114685660A (zh) | 抗cldn18.2抗体及其制备方法和应用 | |
| KR20160131082A (ko) | Lg1-3에 특이적인 항-라미닌4 항체 | |
| CN113135994B (zh) | 一种激活型抗ox40抗体、生产方法及应用 | |
| RU2812910C2 (ru) | Антитела к cd38 и комбинации с антителами к cd3 и cd28 | |
| HK40076013A (en) | Anti-cldn18.2 antibody, and preparation method and use thereof | |
| TW202448504A (zh) | Btn3a活化抗體及免疫檢查點抑制劑之組合 | |
| HK1153502B (en) | Anti-bst2 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170427 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250415 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250415 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260414 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260414 |